metreleptin
Sign in to saveAlso known as Myalept
Metreleptin, sold under the brand name Myalept among others, is a synthetic analog of the hormone leptin used to treat various forms of dyslipidemia. It has been approved in Japan for metabolic disorders including lipodystrophy and in the United States as replacement therapy to treat the complications of leptin deficiency, in addition to diet, in patients with congenital generalized or acquired generalized lipodystrophy.
In the Vinony graph
Vinony's link graph records 145 inbound references to metreleptin, and connects out to lipodystrophy, laronidase and congenital generalized lipodystrophy.
It is catalogued under topics including Chemicals that do not have a ChemSpider ID assigned, Drugs developed by AstraZeneca and Drugs with non-standard legal status.
Vinony links it to 10 Wikipedia language editions.
Key facts
- Drug.H
- 1167
- Drug.N
- 19
- Drug.O
- 221
- Drug.S
- 6
- Drug.image
- Metreleptin.png
- Drug.JAN
- Mettreleptin (genetical recombination)
- Drug.tradename
- Myalept, Myalepta
- Drug.DailyMedID
- Metreleptin
- Drug.routes_of_administration
- Subcutaneous
- Drug.ATC_prefix
- A16
- Drug.ATC_suffix
- AA07
- Drug.legal_CA
- Rx-only
- Drug.legal_CA_comment
- /Schedule D
- Drug.legal_UK
- POM
- Drug.legal_US
- Rx-only
- Drug.legal_EU
- Rx-only
- Drug.legal_status
- Rx-only
- Drug.CAS_number
- 186018-45-1
via Wikipedia infobox
Chemical data
Drug data · ChEMBL
- Max clinical phase
- Approved
- Molecule type
- Protein
- First approval
- 2014
- Admin. routes
- parenteral
- Indications
- obesity, non-alcoholic fatty liver disease, lipodystrophy, metabolic syndrome
via ChEMBL · EBI
Wikidata facts
- Subclass of
- structural analog
- Has use
- medication
Show 3 more facts
- chemical formula
- C₇₁₄H₁₁₆₇N₁₉₁O₂₂₁S₆
- World Health Organisation international non-proprietary name
- metreleptin
- legal status (medicine)
- boxed warning
via Wikidata · CC0
~4 min read
Encyclopedic overview
3 sectionsContents
- Medical uses
- Research
- References
Metreleptin, sold under the brand name Myalept among others, is a synthetic analog of the hormone leptin used to treat various forms of dyslipidemia. It has been approved in Japan for metabolic disorders including lipodystrophy and in the United States as replacement therapy to treat the complications of leptin deficiency, in addition to diet, in patients with congenital generalized or acquired generalized lipodystrophy.
The most common side effects include hypoglycemia and weight loss.
Excerpted from Wikipedia’s “metreleptin” article, available under the CC BY-SA 4.0 licence.